- Entire Pipeline
- Discovery & Early Development
- Pre-clinical & Clinical Development
- Limited Market Availability
Displaying 111 - 120 of 243
Alternative Name: LNG Contraceptive IUS (LCS); LCS16
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Bayer HealthCare
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
Alternative Name: LDH-C4, Lactate dehydrogenase C
Target
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Oral
Developer: Northwestern University
Development Stage: Target Identification
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: ContraMed, LLC
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Pericoital LNG gel
User: Female
Hormonal: Yes
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Population Council
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Zarin; Femplant; Trust; Sino-implant (II)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Marketed
Development Phase: Limited Market Availability
Alternative Name: Leukemia inhibitory factor (LIF) and interleukin-11 (IL-11)
Target
User: Female
Hormonal: No
Duration Type: Short-acting
Developer: Prince Henry's Institute of Medical Research, Australia
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: Levosert (U.K.); Erlacela (Portugal); Donasert (Romania); Avibela
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Actavis, Medicines360
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
Alternative Name: FC-Patch Low; Gestodene (GES) + ethinyl estradiol (EE) Patch
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: WHO HRP, Bayer HealthCare, Gedeon Richter Plc.
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: WHO HRP, CONRAD, NICHD
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Twirla; AG200-15; Levonorgestrel + ethinyl estradiol patch
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Agile Therapeutics
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
Pages
Displaying 51 - 60 of 70
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Innolytics LLC
Development Stage: Lead Optimization
Alternative Name: Proprotein convertase 6
Target
Hormonal: No
Developer: CONRAD, Prince Henry's Institute of Medical Research, Australia
Development Stage: Target Validation
Alternative Name: Phosphodiesterase 3, 5, 9, PDE3A
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, University of Minnesota
Development Stage: Target Identification
User: Female
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Vaginal Gel, Vaginal Ring
Developer: Ottawa Hospital Research Institute (OHRI)
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Vindico NanoBio Technology Inc.
Development Stage: Lead Optimization
Alternative Name: PGE2
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, Bayer HealthCare
Development Stage: Target Identification
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel, Other
Development Stage: Compound ID/Selection
Alternative Name: Retinoic acid receptor (RAR) antagonists
Target
User: Male
Hormonal: No
Duration Type: Short-acting
Developer: NICHD, Columbia University, University of Washington, University of Minnesota
Development Stage: Target Validation
Alternative Name: l-CDB-4022
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Development Stage: Lead Optimization
Alternative Name: Serum- and Glucocorticoid-Regulated Kinase
Target
User: Female
Hormonal: No
Developer: CONRAD, Imperial College, London
Development Stage: Target Identification
Pages
Displaying 81 - 90 of 121
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: University of Washington, GlaxoSmithKline, NICHD
Development Stage: Phase I
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: NIAID, NICHD, Origami Healthcare Products, Inc., Strata Various Product Design
Development Stage: Phase II
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Barrier, Vaginal Ring
Developer: Dare BioScience Inc.
Development Stage: Phase II
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: Vel's College of Pharmacy
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Pericoital
Delivery Method: Oral
Developer: HRA Pharma, Gynuity Health Projects, PATH
Development Stage: Phase III
User: Female
Hormonal: Yes
Duration Type: Pericoital
Delivery Method: Oral
Developer: Stanford University
Development Stage: Phase I
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), FHI 360
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: Vel's College of Pharmacy
Development Stage: Pre-clinical
Alternative Name: Polidocanol Foam Permanent Contraception
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Fallopian Tube
Developer: Oregon Health & Science University
Development Stage: Pre-clinical
Pages
Displaying 11 - 20 of 52
User: Female
Hormonal: Yes
Duration Type: Emergency
Delivery Method: Oral
Developer: HRA Pharma
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Pregna International Limited
Development Stage: Marketed
Alternative Name: ENG + EE Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Amneal
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: HLL Lifecare Limited, Sree Chitra Tirunal Institute for Medical Sciences & Technology (SCTIMST)
Development Stage: Marketed
Alternative Name: Gold T IUD; Novaplus T 380 Ag IUD; Novaplus T 380 Cu IUD; Ancora 375 Ag IUD; Ancora 375 Cu IUD; Ancora 250 Cu Mini IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Eurogine
Development Stage: Marketed
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Famy Care Ltd.
Development Stage: Marketed
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium, APCOR R&M, Belgium
Development Stage: Regulatory
Alternative Name: Fibroplant LNG14 (also LNG 20)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: Regulatory
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Meril Life Science Private Ltd
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Prosan International B.V.
Development Stage: Marketed
Pages
